Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy ASND Stock  Free ASND Stock Alerts

Ascendis Pharma A/S (ASND) Financials

Ascendis Pharma A/S logo
$170.44 +3.86 (+2.32%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Ascendis Pharma A/S

Annual Income Statements for Ascendis Pharma A/S

This table shows Ascendis Pharma A/S's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -36 -72 -149 -149 -245 -512 -434 -624 -533 -391
Consolidated Net Income / (Loss)		 -36 -72 -149 -149 -245 -512 -434 -624 -533 -391
Net Income / (Loss) Continuing Operations		 -36 -72 -149 -149 -245 -512 -434 -624 -533 -391
Total Pre-Tax Income 		-36 -72 -149 -149 -245 -512 -435 -618 -524 -386
Total Operating Income		 -45 -77 -134 -177 -254 -404 -511 -601 -504 -289
Total Gross Profit		 8.82 4.85 1.84 12 15 8.49 4.82 42 246 331
Total Revenue		 8.82 4.85 1.84 12 15 8.49 8.80 55 295 376
Operating Revenue		 8.82 4.85 1.84 12 15 8.49 8.80 55 295 376
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 3.99 13 49 46
Operating Cost of Revenue		 - - - - 0.00 0.00 3.99 13 49 46
Total Operating Expenses		 54 82 136 189 269 412 516 643 750 619
Selling, General & Admin Expense		 10 12 16 29 54 94 181 237 292 301
Research & Development Expense		 44 69 120 161 215 319 335 406 457 318
Total Other Income / (Expense), net		 8.97 4.41 -15 28 9.50 -108 77 -17 -21 -98
Interest Expense		 3.04 3.27 17 0.15 1.37 99 4.43 54 49 104
Interest & Investment Income		 12 7.68 1.11 28 20 2.21 68 56 49 27
Other Income / (Expense), net		 - 0.00 0.00 -0.37 -9.10 -12 14 -19 -20 -21
Income Tax Expense		 -0.71 -0.24 -0.57 -0.45 -0.26 -0.27 -0.42 5.75 8.08 5.01
Basic Earnings per Share		 ($1.39) ($2.58) ($3.68) ($3.17) - - ($7.00) ($11.13) ($9.46) ($6.76)
Weighted Average Basic Shares Outstanding		 23.77M 26.56M 33.63M 41.09M 46.51M 50.62M 54.77M 56.07M 56.29M 57.89M
Diluted Earnings per Share		 ($1.39) ($2.58) ($3.68) ($3.17) - - ($7.00) ($11.13) ($9.46) ($6.76)
Weighted Average Diluted Shares Outstanding		 23.77M 26.56M 38.00M 41.09M 52.19M 50.62M 56.94M 57.15M 57.71M 60.69M
Weighted Average Basic & Diluted Shares Outstanding		 - 26.56M 38.00M 41.09M 52.19M 50.62M 56.94M 57.15M 57.71M 60.69M

Quarterly Income Statements for Ascendis Pharma A/S

No quarterly income statements for Ascendis Pharma A/S are available.

Annual Cash Flow Statements for Ascendis Pharma A/S

This table details how cash moves in and out of Ascendis Pharma A/S's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 67 60 34 71 351 49 -200 -40 -52 150
Net Cash From Operating Activities		 -47 -63 -114 -159 -197 -332 -473 -530 -517 -298
Net Cash From Continuing Operating Activities		 -47 -63 -113 -146 -195 -327 -476 -528 -514 -298
Net Income / (Loss) Continuing Operations		 -36 -72 -149 -149 -245 -512 -434 -624 -533 0.00
Non-Cash Adjustments To Reconcile Net Income		 -7.10 3.43 28 -0.83 44 174 51 92 129 -292
Changes in Operating Assets and Liabilities, net		 -4.92 4.86 6.87 3.15 -1.90 -1.68 -110 -15 -131 -5.71
Net Cash From Investing Activities		 -1.13 -0.71 -1.13 -3.03 -5.79 -356 -125 66 317 -0.49
Net Cash From Continuing Investing Activities		 -1.13 -0.71 -1.13 -3.03 -5.79 -362 -125 71 320 -0.49
Purchase of Property, Plant & Equipment		 -1.13 -0.71 -1.13 -3.03 -5.79 -24 -27 - - -1.48
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.00 0.06 0.98
Sale and/or Maturity of Investments		 - - - 0.00 0.00 321 170 300 320 0.00
Net Cash From Financing Activities		 115 124 150 233 554 736 398 424 149 448
Net Cash From Continuing Financing Activities		 115 124 150 233 554 736 398 424 151 448
Repayment of Debt		 - - 0.00 0.00 -4.53 -5.83 -7.28 -6.80 -12 -12
Repurchase of Common Equity		 -9.12 -8.95 -10 -15 0.00 0.00 -24 -113 0.00 0.00
Issuance of Debt		 -0.14 - - - - - 0.00 538 151 139
Issuance of Common Equity		 124 133 160 248 539 709 416 0.00 0.00 321

Quarterly Cash Flow Statements for Ascendis Pharma A/S

No quarterly cash flow statements for Ascendis Pharma A/S are available.

Annual Balance Sheets for Ascendis Pharma A/S

This table presents Ascendis Pharma A/S's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 200 253 365 759 1,197 1,228 1,166 913 1,221
Total Current Assets		 190 238 335 686 904 885 955 727 1,069
Cash & Equivalents		 190 235 318 671 714 505 476 434 579
Accounts Receivable		 - 1.92 2.04 7.72 11 27 29 61 182
Inventories, net		 - - - - 0.00 85 140 231 306
Current Deferred & Refundable Income Taxes		 0.78 0.93 0.97 - - - - 0.89 1.84
Plant, Property, & Equipment, net		 2.47 3.07 4.95 51 132 141 130 86 -0.45
Plant, Property & Equipment, gross		 -4.58 3.07 4.95 51 132 141 130 86 -0.45
Total Noncurrent Assets		 12 13 39 104 469 200 72 51 46
Long-Term Investments		 - 0.00 20 17 152 165 33 6.29 14
Noncurrent Note & Lease Receivables		 - - - - - - - 2.35 2.40
Other Noncurrent Operating Assets		 8.49 8.65 16 82 310 29 34 43 29
Total Liabilities & Shareholders' Equity		 200 253 365 759 1,197 1,228 1,166 696 920
Total Liabilities		 14 29 45 89 172 228 884 1,074 1,330
Total Current Liabilities		 14 29 45 32 27 70 108 108 102
Accounts Payable		 14 29 37 31 27 67 108 105 100
Current Deferred & Payable Income Tax Liabilities		 - 0.00 0.01 0.13 - - - 2.54 1.26
Other Current Liabilities		 - 0.00 7.90 0.96 0.44 2.94 - 1.31 0.97
Total Noncurrent Liabilities		 0.10 0.00 0.00 57 145 155 767 749 928
Long-Term Debt		 - - - - - 119 544 697 852
Other Noncurrent Operating Liabilities		 - - - 16 32 37 218 52 76
Total Equity & Noncontrolling Interests		 186 225 321 670 1,025 1,000 282 -161 -109
Total Preferred & Common Equity		 186 225 321 670 1,025 1,000 282 -161 -109
Total Common Equity		 186 225 321 670 1,025 1,000 282 -161 -109
Common Stock		 - 5.97 6.48 7.23 8.82 8.65 8.21 8.57 8.44
Other Equity Adjustments		 186 219 314 663 1,016 991 274 -170 -118

Quarterly Balance Sheets for Ascendis Pharma A/S

No quarterly balance sheets for Ascendis Pharma A/S are available.

Annual Metrics and Ratios for Ascendis Pharma A/S

This table displays calculated financial ratios and metrics derived from Ascendis Pharma A/S's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% -45.07% -62.07% 558.91% 23.95% -43.41% 3.64% 521.89% 438.93% 27.58%
EBITDA Growth		 0.00% -69.50% -75.14% -32.59% -45.08% -57.78% -18.89% -25.08% 16.21% 38.55%
EBIT Growth		 0.00% -68.80% -74.66% -32.47% -48.48% -57.67% -19.78% -24.56% 15.44% 41.00%
NOPAT Growth		 0.00% -68.80% -74.66% -32.19% -43.65% -58.74% -26.60% -17.54% 16.16% 42.74%
Net Income Growth		 0.00% -101.47% -106.52% -0.04% -64.32% -109.18% 15.18% -43.71% 14.64% 26.52%
EPS Growth		 0.00% -85.61% -42.64% 13.86% 0.00% 0.00% 0.00% -58.94% 14.99% 28.53%
Operating Cash Flow Growth		 0.00% -34.05% -80.45% -39.06% -24.29% -68.01% -42.50% -12.19% 2.51% 42.41%
Free Cash Flow Firm Growth		 0.00% 0.00% -49.19% -41.56% -149.56% -101.24% 76.09% -74.94% -148.77% 53.79%
Invested Capital Growth		 0.00% 0.00% -724.65% -74.34% 663.87% 315.68% -54.50% -96.56% 4,112.33% 30.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 54.71% 76.28% 83.36% 87.83%
EBITDA Margin		 -508.34% -1,568.45% -7,242.29% -1,457.31% -1,705.74% -4,756.16% -5,455.90% -1,097.34% -170.60% -82.18%
Operating Margin		 -515.21% -1,583.15% -7,290.26% -1,462.59% -1,695.10% -4,755.07% -5,808.59% -1,097.85% -170.80% -76.66%
EBIT Margin		 -515.21% -1,583.15% -7,290.26% -1,465.63% -1,755.75% -4,892.05% -5,653.78% -1,132.43% -177.69% -82.18%
Profit (Net Income) Margin		 -405.54% -1,487.30% -8,097.84% -1,229.53% -1,630.03% -6,025.53% -4,931.56% -1,139.63% -180.51% -103.97%
Tax Burden Percent		 98.06% 99.67% 99.62% 99.70% 99.89% 99.95% 99.90% 100.93% 101.54% 101.30%
Interest Burden Percent		 80.27% 94.26% 111.51% 84.15% 92.94% 123.23% 87.31% 99.71% 100.04% 124.90%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -6,860.75% 0.00% 0.00% -450.45% -114.07% -123.13% -447.45% -261.59% -66.58%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -6,840.81% 0.00% 0.00% -435.85% -75.86% -112.58% -410.30% -502.75% -109.74%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 6,783.17% 0.00% 0.00% 401.06% 53.67% 80.25% 350.11% -621.92% 355.84%
Return on Equity (ROE)		 0.00% -77.58% -72.48% -54.60% -49.40% -60.40% -42.88% -97.35% -883.51% 289.26%
Cash Return on Invested Capital (CROIC)		 0.00% -7,060.75% 0.00% 0.00% -303.02% -236.50% -48.21% -260.76% -452.31% -92.91%
Operating Return on Assets (OROA)		 0.00% -38.36% -59.10% -57.39% -46.87% -42.48% -41.05% -51.80% -50.43% -28.99%
Return on Assets (ROA)		 0.00% -36.04% -65.65% -48.15% -43.52% -52.32% -35.81% -52.13% -51.23% -36.68%
Return on Common Equity (ROCE)		 0.00% -77.58% -72.48% -54.60% -49.40% -60.40% -42.88% -97.35% -883.51% 289.26%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -38.79% -66.18% -46.45% -36.51% -49.95% -43.41% -221.45% 330.44% 357.68%
Net Operating Profit after Tax (NOPAT)		 -32 -54 -94 -124 -178 -283 -358 -421 -353 -202
NOPAT Margin		 -360.65% -1,108.21% -5,103.18% -1,023.82% -1,186.57% -3,328.55% -4,066.01% -768.50% -119.56% -53.66%
Net Nonoperating Expense Percent (NNEP)		 0.00% -19.94% -26.28% -8.71% -14.60% -38.21% -10.56% -37.15% 241.17% 43.17%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -50.96% -65.83% -27.19%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 45.29% 23.72% 16.64% 12.17%
SG&A Expenses to Revenue		 115.98% 249.76% 881.18% 236.81% 362.41% 1,102.68% 2,059.40% 432.30% 99.13% 80.06%
R&D to Revenue		 499.24% 1,433.39% 6,509.08% 1,325.78% 1,432.68% 3,752.39% 3,803.90% 741.83% 155.02% 84.43%
Operating Expenses to Revenue		 615.21% 1,683.15% 7,390.26% 1,562.59% 1,795.10% 4,855.07% 5,863.29% 1,174.13% 254.15% 164.49%
Earnings before Interest and Taxes (EBIT)		 -45 -77 -134 -177 -264 -416 -498 -620 -524 -309
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -76 -133 -176 -256 -404 -480 -601 -503 -309
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 7.23 8.75 7.81 7.23 24.68 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 7.32 8.80 7.86 7.27 25.14 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 191.33 390.53 942.22 821.42 127.02 24.40 21.11
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 54.24 17.73 35.27 1,067.84 28.30 23.89
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 163.46 347.38 834.17 728.46 121.99 25.27 21.79
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.06 0.11 0.12 1.93 -4.32 -7.79
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.06 0.11 0.12 1.93 -4.32 -7.79
Financial Leverage		 0.00 -0.99 -1.02 -1.05 -0.92 -0.71 -0.71 -0.85 1.24 -3.24
Leverage Ratio		 0.00 1.08 1.10 1.13 1.14 1.15 1.20 1.87 17.25 -7.89
Compound Leverage Factor		 0.00 1.01 1.23 0.95 1.06 1.42 1.05 1.86 17.25 -9.85
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 5.78% 9.88% 10.62% 65.88% 130.08% 114.73%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 5.78% 9.88% 10.62% 65.88% 130.08% 114.73%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 94.22% 90.12% 89.38% 34.12% -30.08% -14.73%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.16 -0.28 -0.25 -0.91 -1.38 -2.76
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 2.53 2.27 1.70 0.46 -0.51 -0.84
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.16 -0.28 -0.25 -0.91 -1.38 -2.76
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.23 -0.40 -0.33 -1.29 -1.98 -4.22
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 3.64 3.25 2.29 0.65 -0.73 -1.28
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.23 -0.40 -0.33 -1.29 -1.98 -4.22
Altman Z-Score		 0.00 0.00 0.00 30.60 39.27 27.60 18.51 3.88 3.26 4.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 13.85 8.32 7.53 21.26 33.25 12.60 8.84 6.70 10.48
Quick Ratio		 0.00 13.79 8.29 7.19 21.05 32.68 11.39 7.54 4.56 7.46
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -55 -82 -117 -291 -586 -140 -245 -610 -282
Operating Cash Flow to CapEx		 -4,183.45% -8,955.21% -10,106.16% -5,241.77% -3,410.27% -1,367.31% -1,761.93% 0.00% 0.00% -60,297.87%
Free Cash Flow to Firm to Interest Expense		 0.00 -16.88 -4.99 -802.98 -212.57 -5.94 -31.66 -4.54 -12.51 -2.72
Operating Cash Flow to Interest Expense		 -15.54 -19.34 -6.91 -1,092.93 -144.09 -3.36 -106.79 -9.82 -10.61 -2.88
Operating Cash Flow Less CapEx to Interest Expense		 -15.91 -19.55 -6.98 -1,113.78 -148.32 -3.60 -112.85 -9.82 -10.61 -2.88
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.02 0.01 0.04 0.03 0.01 0.01 0.05 0.28 0.35
Accounts Receivable Turnover		 0.00 0.00 0.00 6.12 3.08 0.92 0.46 1.96 6.61 3.10
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.26 0.17
Fixed Asset Turnover		 0.00 1.96 0.66 3.02 0.54 0.09 0.06 0.40 2.73 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.15 0.46 0.45
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 59.65 118.61 394.66 786.31 186.02 55.26 117.64
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,164.44 1,378.38 2,139.67
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 4,302.27 2,464.40 790.40 814.22
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 59.65 118.61 394.66 -3,515.96 886.06 643.23 1,443.10
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 1.57 -9.78 -17 96 400 182 6.25 263 343
Invested Capital Turnover		 0.00 6.19 -0.45 -0.90 0.38 0.03 0.03 0.58 2.19 1.24
Increase / (Decrease) in Invested Capital		 0.00 1.57 -11 -7.27 113 303 -218 -176 257 80
Enterprise Value (EV)		 0.00 0.00 0.00 1,979 5,214 7,085 6,413 6,678 7,455 8,204
Market Capitalization		 0.00 0.00 0.00 2,317 5,862 8,003 7,231 6,954 7,198 7,945
Book Value per Share		 $0.00 $6.99 $6.69 $8.67 $15.90 $21.35 $18.61 $4.95 ($2.82) ($1.90)
Tangible Book Value per Share		 $0.00 $6.86 $6.56 $8.56 $15.81 $21.21 $18.50 $4.86 ($2.82) ($1.90)
Total Capital		 0.00 186 225 321 711 1,137 1,119 826 536 743
Total Debt		 0.00 0.00 0.00 0.00 41 112 119 544 697 852
Total Long-Term Debt		 0.00 0.00 0.00 0.00 41 112 119 544 697 852
Net Debt		 0.00 -190 -235 -338 -648 -918 -818 -275 257 259
Capital Expenditures (CapEx)		 1.13 0.71 1.13 3.03 5.79 24 27 0.00 -0.06 0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -13 -26 -27 -18 -1.13 42 60 184 388
Debt-free Net Working Capital (DFNWC)		 0.00 177 209 291 654 877 814 847 618 967
Net Working Capital (NWC)		 0.00 177 209 291 654 877 814 847 618 967
Net Nonoperating Expense (NNE)		 3.96 18 55 25 67 229 76 203 180 189
Net Nonoperating Obligations (NNO)		 0.00 -184 -235 -338 -574 -625 -818 -275 425 453
Total Depreciation and Amortization (D&A)		 0.61 0.71 0.88 1.01 7.51 12 17 19 21 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -267.87% -1,398.17% -225.62% -117.24% -13.26% 481.97% 110.02% 62.48% 102.99%
Debt-free Net Working Capital to Revenue		 0.00% 3,647.22% 11,369.87% 2,400.43% 4,354.58% 10,324.65% 9,251.12% 1,547.19% 209.52% 256.86%
Net Working Capital to Revenue		 0.00% 3,647.22% 11,369.87% 2,400.43% 4,354.58% 10,324.65% 9,251.12% 1,547.19% 209.52% 256.86%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.68) ($3.17) ($4.69) ($8.28) $0.00 $0.00 ($8.55) ($6.76)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 33.63M 41.09M 46.51M 50.62M 54.77M 56.07M 56.29M 57.89M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.68) ($3.17) ($4.69) ($8.28) $0.00 $0.00 ($8.55) ($6.76)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 33.63M 42.14M 47.99M 53.75M 56.94M 57.15M 57.71M 60.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($3.17) ($4.69) ($8.28) $0.00 $0.00 ($8.55) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 36.98M 42.14M 47.99M 53.75M 56.94M 57.15M 57.71M 60.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -54 -94 -124 -178 -283 -358 -421 -353 -202
Normalized NOPAT Margin		 -360.65% -1,108.21% -5,103.18% -1,023.82% -1,186.57% -3,328.55% -4,066.01% -768.50% -119.56% -53.66%
Pre Tax Income Margin		 -413.57% -1,492.23% -8,129.02% -1,233.26% -1,631.78% -6,028.68% -4,936.28% -1,129.12% -177.77% -102.64%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -14.95 -23.43 -8.11 -1,221.08 -192.33 -4.21 -112.44 -11.48 -10.76 -2.99
NOPAT to Interest Expense		 -10.47 -16.40 -5.68 -852.99 -129.98 -2.86 -80.86 -7.79 -7.24 -1.95
EBIT Less CapEx to Interest Expense		 -15.33 -23.65 -8.18 -1,241.94 -196.55 -4.45 -118.50 -11.48 -10.75 -2.99
NOPAT Less CapEx to Interest Expense		 -10.84 -16.62 -5.74 -873.84 -134.20 -3.11 -86.92 -7.79 -7.24 -1.96
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -25.50% -12.41% -6.77% -10.08% 0.00% 0.00% -5.63% -18.06% 0.00% 0.00%

Quarterly Metrics and Ratios for Ascendis Pharma A/S

No quarterly metrics and ratios for Ascendis Pharma A/S are available.

Frequently Asked Questions About Ascendis Pharma A/S's Financials

When does Ascendis Pharma A/S's fiscal year end?

According to the most recent income statement we have on file, Ascendis Pharma A/S's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ascendis Pharma A/S's net income changed over the last 9 years?

Ascendis Pharma A/S's net income appears to be on an upward trend, with a most recent value of -$391.35 million in 2024, rising from -$35.77 million in 2015. The previous period was -$532.58 million in 2023.

What is Ascendis Pharma A/S's operating income?
Ascendis Pharma A/S's total operating income in 2024 was -$288.55 million, based on the following breakdown:
  • Total Gross Profit: $330.59 million
  • Total Operating Expenses: $619.14 million
How has Ascendis Pharma A/S revenue changed over the last 9 years?

Over the last 9 years, Ascendis Pharma A/S's total revenue changed from $8.82 million in 2015 to $376.40 million in 2024, a change of 4,167.4%.

How much debt does Ascendis Pharma A/S have?

Ascendis Pharma A/S's total liabilities were at $1.33 billion at the end of 2024, a 23.8% increase from 2023, and a 9,296.3% increase since 2016.

How much cash does Ascendis Pharma A/S have?

In the past 8 years, Ascendis Pharma A/S's cash and equivalents has ranged from $189.71 million in 2016 to $714.05 million in 2020, and is currently $579.18 million as of their latest financial filing in 2024.

How has Ascendis Pharma A/S's book value per share changed over the last 9 years?

Over the last 9 years, Ascendis Pharma A/S's book value per share changed from 0.00 in 2015 to -1.90 in 2024, a change of -189.6%.


Related Companies

This page (NASDAQ:ASND) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners
Feds Just Admitted It—They Can Take Your Cash
Here’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...
Priority Gold | Sponsored
M.A.G.A. is Finished – This Could be even Better
You’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...
Paradigm Press | Sponsored
Secret financial plot unfolding in Washington DC… [DEVELOPING]
What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...
Timothy Sykes | Sponsored
You’re About to Lose Everything – Act Now or Regret It Forever
What If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...
Hamilton Gold Group | Sponsored
This isn’t a trade war. It’s worse…
Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...
Stansberry Research | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...
Altimetry | Sponsored